Form 4: J&J CFO Joseph Wolk Reports Routine Equity Transactions

Johnson & Johnson's Executive VP and CFO, Joseph J. Wolk, reported a series of equity transactions including vesting of awards, tax-related dispositions, and option exercises and sales.

Summary

• Joseph J. Wolk, Executive VP and CFO of Johnson & Johnson (JNJ), reported multiple transactions involving common stock and derivative securities.
• Transactions included the vesting and conversion of Performance Share Units (PSUs) and Restricted Share Units (RSUs) into common stock on February 13, 2026, and February 15, 2026.
• Shares totaling 18,130 were withheld for tax obligations upon the vesting of PSUs and RSUs.
• Wolk exercised employee stock options and subsequently sold the acquired common stock: 19,241 shares acquired at $115.67 and sold at a weighted average of $242.99; 12,066 shares acquired at $129.51 and sold at $242.87; and 33,386 shares acquired at $131.94 and sold at $242.75.
• An additional 24,961 shares of common stock were sold on February 17, 2026, at a weighted average price of $242.68.
• New awards of derivative securities were reported on February 15, 2026, including 53,793 employee stock options and 3,863 Restricted Share Units (RSUs).
• Following these transactions, Wolk directly owns 14,000 shares of common stock.
• Indirect beneficial ownership includes 68,835 shares held in a spousal lifetime access trust (SLAT) and 2,173 shares in a 401k plan, totaling 71,008 indirect shares.
• Total beneficial ownership of common stock (direct and indirect) is 85,008 shares.
• Remaining derivative holdings include 86,793 employee stock options and 9,588 Restricted Share Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report. While there are significant sales of common stock, these appear largely tied to the exercise of options and tax obligations from vesting equity, which are routine for executive compensation. The executive also received new equity awards, indicating continued alignment.

Positives

• Vesting of Performance Share Units (PSUs) and Restricted Share Units (RSUs) indicates the achievement of performance or time-based milestones.
• New awards of 53,793 employee stock options and 3,863 Restricted Share Units demonstrate continued incentive alignment with the company's long-term performance.
• The exercise of options at lower strike prices ($115.67, $129.51, $131.94) and subsequent sale at significantly higher market prices (around $242-$244) indicates profitable transactions for the executive.

Negatives

• Significant sales of common stock, totaling 107,784 shares, including shares sold after option exercises and an additional 24,961 shares, represent a reduction in direct equity exposure.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity awards like PSUs, RSUs, and stock options, is a standard practice across the pharmaceutical and consumer health industries. These mechanisms are designed to align executive interests with shareholder value creation over the long term. The reported transactions reflect a typical cycle of vesting, tax-related dispositions, and option exercises common among senior executives in large, established companies like Johnson & Johnson.

Related Party Transactions

• 68,835 shares of common stock are held indirectly in a Spousal Lifetime Access Trust (SLAT), of which the reporting person's spouse is the trustee and beneficiary.

Stakeholder Impact

• Shareholders: The transactions reflect routine executive compensation activities. The sales, while significant in volume, are often expected as executives monetize vested equity and cover tax liabilities. New awards align executive interests with long-term shareholder value.
• Employees: The report details executive compensation, which is part of the broader compensation structure within the company.
• Customers/Suppliers/Creditors: No direct impact from these insider transactions.

Next Steps

• Future vesting of Restricted Share Units (RSUs) awarded on February 15, 2024, and February 15, 2025, in annual equal installments.
• Future vesting of new Restricted Share Units (RSUs) awarded on February 15, 2026, in three annual equal installments.
• Future vesting of new Employee Stock Options awarded on February 15, 2026, in three equal annual installments.
• Future exercisability of remaining Employee Stock Options according to their vesting schedules.

Key Dates

Recommendation

The filing details routine executive compensation activities, including the vesting of equity awards, sales to cover tax obligations, and the exercise and sale of stock options, all conducted under a pre-arranged 10b5-1 plan. While there are significant sales, these are largely offset by option exercises and new awards, and do not suggest a change in the company's fundamental outlook or the executive's long-term commitment. Therefore, a 'hold' recommendation is appropriate as these transactions are not indicative of new material information that would alter an investment thesis.

Keywords

Johnson & Johnson, JNJ, Joseph J. Wolk, SEC Form 4, insider trading, common stock, stock options, restricted share units, performance share units, executive compensation, beneficial ownership